Polyoxidonium (azoximer bromide) - the Russian original drug produced by Petrovax-  was approved by the Ministry of Health of the Russian Federation for conducting an international clinical trial for the treatment of COVID-19.

Vladimir Potanin spoke at the celebration marking the 20th anniversary of his Foundation. He outlined his vision for the future of the Foundation and explained what parameters he uses to evaluate its work. He believes that charitable work has to take into account feedback: social needs and demands.

In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.